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The p75 neurotrophin receptor (p75NTR) has been
shown to mediate neuronal death through an unknown
pathway. We microinjected p75NTR expression plas-
mids into sensory neurons in the presence of growth
factors and assessed the effect of the expressed proteins
on cell survival. We show that, unlike other members of
the TNFR family, p75NTR signals death through a
unique caspase-dependent death pathway that does not
involve the “death domain” and is differentially regu-
lated by Bcl-2 family members: the anti-apoptotic mole-
cule Bcl-2 both promoted, and was required for, p75NTR
killing, whereas killing was inhibited by its homologue
Bcl-xL. These results demonstrate that Bcl-2, through
distinct molecular mechanisms, either promotes or in-
hibits neuronal death depending on the nature of the
death stimulus.
The neurotrophin receptor, p75NTR,1 is required along with
the trkA receptor for high affinity NGF binding and neuronal
survival (1); however, more recently it was shown to be in-
volved in promoting cell death by an unknown pathway. Over-
expression of p75NTR increased neuronal death both in vitro
and in vivo (2–4), and lowering the expression of p75NTR was
shown to prevent neuronal death after growth factor with-
drawal in vitro, and after sciatic nerve axotomy (5, 6). Addi-
tionally, p75NTR-dependent cell death occurred after activa-
tion by NGF or brain-derived neurotrophic factor (BDNF) in
cells, respectively, lacking trkA or trkB expression (7–10).
p75NTR is a member of the tumor necrosis factor receptor
(TNFR) superfamily, showing homology in the extracellular
ligand binding domain and a cytoplasmic motif known as the
“death domain,” so called because of the cytotoxic actions of
proteins containing the domain (11). The death signaling path-
way of the TNFR family is well characterized, typically involv-
ing other “death domain”-containing proteins (12), and is not
inhibited by the anti-apoptotic proteins Bcl-2 or Bcl-xL. These
Bcl-2 family members are well characterized inhibitors of
stress-induced cell death, blocking neuronal cell death in a
variety of models (13–15).
Herein we investigate the role of the death domain and Bcl-2
family members in mediating p75NTR death signaling using
microinjection technology to deliver expression plasmids into
cultured neurons. We show that the p75NTR death signaling
pathway is unlike the TNFR death signaling pathway as an
intracellular juxta-membrane domain, and not the death do-
main, of p75NTR is sufficient and required to mediated death
signaling. Secondly, the anti-apoptotic Bcl-2 family members
that have little influence on TNFR death signaling have pro-
found effects on the p75NTR death pathway.
MATERIALS AND METHODS
Cell Culture—Dorsal root ganglia were dissected from postnatal day
zero C57Bl/6 or Bcl-2-deficient mice and plated in 3-cm tissue dishes
precoated with poly-DL-ornithine (500 mg/ml, Sigma) and laminin (20
mg/ml, Life Technologies, Inc.) at a density of 5000 neurons/dish (5).
Cells were grown in Monomed medium (CSL, Melbourne, Australia)
containing 1% fetal bovine serum and leukemia inhibitory factor (LIF,
AMRAD, Australia) or nerve growth factor (2.5 S NGF, 50 ng/ml,
Alomone Laboratories). Survival of sensory neurons was assessed by
morphological criteria (5) and propidium iodide exclusion. Heterozy-
gous mice containing a disrupted Bcl-2 gene, (D. Loh, Roche, Japan)
were mated to produce litters contains homozygous Bcl-2 knock-out
mice. The genotypes of newborn mice were determined by polymerase
chain reaction, and results were confirmed by staining of thymocytes
with an anti-mouse Bcl-2 antibody (PharMingen) before dissection and
microinjection of neurons isolated from individual mice of appropriate
genotype.
Microinjection—Sensory neurons were injected into the nucleus with
a solution containing plasmid (100 mg/ml, with the exception of Bcl-2,
which was at 50 mg/ml), tetramethylrhodamine dextran (“fluoro-ruby,”
0.15%, Molecular Probes), and phosphate-buffered saline. Where more
than one plasmid was expressed in a single condition, only one injection
of solution containing all plasmids was made, with the individual plas-
mid concentrations as specified above. Approximately 70 neurons/well
were injected, with two or three wells comprising each condition. At
least 2 h after completion of the injections, the number of fluoro-ruby
containing cells that had survived the injection procedure was counted,
and this provided the time zero 100% value for each well.
Immunostaining—Cells were fixed with 4% paraformaldehyde for 15
min and then stained with an anti-rat-p75NTR antibody (MC192,
Roche Molecular Biochemicals) (3) or anti-human-Bcl-2 antibody (Bcl-
2/100, (PharMingen).
DNA Constructs—The plasmid containing the full-length rat
p75NTR cDNA, p75NTR, is described (4), and all p75NTR plasmids are
modified versions of this original expression vector. A control plasmid,
p75NTRnc (no cytoplasmic domain) is missing the entire cytoplasmic
domain except the membrane anchoring Lys-274 and Arg-275.
p75NTRtr is truncated with an I308A substitution followed by a stop
codon, deleting the entire death domain. p75NTRD retains Lys-274 and
Arg-275 and the last 108 amino acids creating a cytoplasmic domain
including the death domain but deleted for the 33-amino acid juxta-
membrane domain retained by p75NTRtr. All plasmids were con-
structed using polymerase chain reaction to amplify desired coding
regions followed by subcloning the polymerase chain reaction products
into plasmid vectors. Details of primers used in construction of these
plasmids are available on request. Bcl-2 and Bcl-xL plasmids are pre-
viously described (16, 17). The modified CrmA has the caspase recog-
nition sequence modified from wild-type Leu-Glu-Ala-Asp to
Asp-Gln-Met-Asp.
Yeast Two-hybrid Methods—The p75NTR death domain from Leu-
342 on was cloned into pGBT9 (CLONTECH) and used to screen a
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C57Bl/6 P2 dorsal root ganglia neuron library cloned into the HybriZap
vector (Stratagene). No death domain proteins were isolated. Interac-
tions between the p75NTR death domain and other known death sig-
naling proteins (FADD death domain, full-length FADD, IAP1, Trafs
1–6) cloned into pGAD10 (CLONTECH) were tested by sequential yeast
transformation for growth on media selective for an interaction.
RESULTS
To investigate whether p75NTR signals death through inter-
action with death domain containing proteins or via another
pathway, we have activated the p75NTR pathway in a similar
fashion to experiments that use ligand-free overexpression of
TNFR to study apoptosis (18). We overexpressed p75NTR in
neurons by microinjecting a rat p75NTR expression plasmid
into the nucleus of mouse dorsal root ganglia sensory neurons
(Fig. 1) and cultured them in the presence of the neural cyto-
kine, LIF, to prevent p75NTR-independent neuronal death.
These neurons were chosen because we had previously shown
that their death was, at least in part, mediated by p75NTR (5,
6). It was found after 16 h that approximately 20–25% of
neurons injected with full-length p75NTR plasmid died (Fig.
2A), compared with neurons injected with a control b-galacto-
sidase plasmid or a truncated p75NTR protein lacking the
entire cytoplasmic domain (p75NTRnc) expressed to a similar
extent. The majority of the p75NTR-mediated death was ob-
served in the first 16 h (see Fig. 3C for example), comparable
FIG. 1. Microinjection of sensory neuron with p75NTR plas-
mid. A, photomicrograph of mouse postnatal day zero sensory neuron
being co-injected with rat p75NTR plasmid and fluoro-ruby. B, phase-
contrast photomicrograph of an injected neuron that has been cultured
for 24 h in NGF, showing fluoro-ruby (panel C) and extensive rat
p75NTR expression (panel D) as revealed by immunofluorescence stain-
ing with anti-rat-specific antibody. Expression of a Green Fluorescence
Protein plasmid (CLONTECH) was detectable as early as 6 h after
injection, and surface rat p75NTR was strongly expressed in over 80%
of injected neurons by the end of the experiment. Bar 5 100 mm in
panels A–C, and 200 mm in panel D.
FIG. 2. Effect of p75NTR overexpression on mouse sensory
neuron survival. A, overexpression of p75NTR resulted in a signifi-
cant (* p , 0.5) increase in neuronal cell death when compared with
p75NTRnc or control b-galactosidase plasmid. Shown is a representa-
tive experiment, and from eight separate experiments there was an
average increase in cell death of 21%. Neurons are cultured in the
presence of survival-promoting growth factor LIF. B, schematic of dif-
ferent p75NTR proteins expressed from plasmids injected into neurons
(i), and their effect on neuronal survival compared with p75NTR (100%)
and p75NTRnc (0%) after 16 h (ii). Only the proteins containing the
juxta-membrane portion killed; whereas the construct that contains
only the death domain was ineffective. Error bars indicate S.E., n 5 3.
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with that reported for TNFR overexpression (18).
Because the cytoplasmic tail of p75NTR is required for the
cytotoxic effect, we next examined whether deletion of the
death domain also abolished the ability of p75NTR to kill.
Surprisingly, the neuronal death observed after expression of
p75NTR with a truncated cytoplasmic tail (p75NTRtr), lacking
the death domain, was not significantly different from that
observed with full-length p75NTR (Fig. 2B). Furthermore, a
deletion p75NTR protein (p75NTRD), containing the death do-
main but deleted for the juxta-membrane portion, did not in-
duce significant death (Fig. 2B). Thus, the death domain was
not required for p75NTR killing, and the juxta-membrane cy-
toplasmic tail is necessary and sufficient for killing. The
p75NTR death domain has recently been shown to have a
different tertiary structure to the death domain of the TNFR
family and does not self-associate in vitro (19), supporting the
finding that the p75NTR death domain does not function to
induce death. Using the yeast two-hybrid method to find
p75NTR death domain binding partners, we found no evidence
of specific interaction with other death domain-containing pro-
teins (see “Materials and Methods”). Together, these results
suggest that an alternative pathway to one involving death
domain adapter proteins, such as TRADD and FADD, may be
responsible for p75NTR-mediated killing.
To further explore whether p75NTR killing was different
from TNFR killing pathways, we examined whether overex-
pression of the anti-apoptotic Bcl-2 family proteins could in-
hibit killing by p75NTR. Bcl-2 and Bcl-xL are well character-
ized inhibitors of growth factor withdrawal and stress-induced
apoptosis (15). However, both proteins are poor inhibitors of
CD95/Apo1/Fas and TNFR-mediated apoptosis (20, 21).
We found that overexpression of Bcl-xL protected neurons
against p75NTR-induced death (Fig. 3A), supporting the hy-
pothesis that p75NTR signals through an alternative pathway
to TNFR-induced apoptosis. Whereas Bcl-2 overexpression
alone had no effect on cell survival in the presence of LIF (Fig.
3B), Bcl-2 in combination with p75NTR overexpression, sur-
prisingly, enhanced the neuronal death seen with p75NTR
overexpression alone, yet in combination with p75NTRnc it had
no effect (Fig. 3B). The results are surprising because Bcl-2 is
functionally indistinguishable from Bcl-xL in most cell-death
systems (16, 22), yet in this assay we find that they have
opposite effects (Fig. 3C). The cell death observed with p75NTR
and Bcl-2 overexpression was totally ablated if the cells were
cultured in NGF, confirming that signaling though trk may
inhibit p75NTR activity (Fig. 3D). Bcl-2 was able to protect
against neuronal death induced by NGF withdrawal (Fig. 3E).
Thus, at the same expression levels in the same neuronal
population, Bcl-2 was able to inhibit or enhance neuronal cell
death depending on the nature of the death signal.
To determine whether the paradoxical effect of Bcl-2 on
p75NTR-induced killing was related to its known anti-apop-
totic activity, inactive Bcl-2 mutants were utilized (17). Like
wild-type Bcl-2, expression of the Bcl-2 mutants did not affect
neuronal survival. In combination with p75NTR expression,
the enhanced killing effect seen with Bcl-2 co-expression was
abrogated by expression of the mutant G145E Bcl-2, suggesting
the protein was nonfunctional (Fig. 4A). Thus, an intact BH1
homology region is required for both the survival and death
promoting activities of Bcl-2. Using a W188A mutated Bcl-2, we
found that co-expression with p75NTR not only abolished the
increased p75NTR killing but, more importantly, protected
neurons from any p75NTR-induced death (Fig. 4B), reminis-
cent of that seen with Bcl-xL, despite being unable to protect
against growth factor withdrawal-induced death (17). Thus,
the mechanism by which Bcl-2 participates in the death path-
way is separable from its function in the survival pathway.
Bcl-2 has previously been observed to increase cell death
when highly expressed both in vitro and in vivo (23–25). Thus,
it is possible that the high level of Bcl-2 is able to “prime” the
FIG. 3. Effect of Bcl-xL and Bcl-2 expression plasmids on
p75NTR-mediated killing. A, Bcl-xL and p75NTR plasmids were
co-injected into neurons in the presence of LIF, and survival 16 h after
injection was assessed. Bcl-xL was able to totally rescue neurons from
p75NTR-mediated cell death. Note also that neurons injected with
Bcl-xL had increased survival compared with Fig. 2A. B, although the
survival of neurons in the presence of LIF was not affected by expres-
sion of Bcl-2 plasmid alone (compare with Fig. 2A), in combination with
p75NTR there was a significant increase in cell death. The ability of
Bcl-2 to promote cell death because of full-length p75NTR is not seen in
the presence of p75NTRnc. C, Bcl-2 and Bcl-xL have opposite effects on
the p75NTR-mediated killing within the first 16 h after injection. D,
microinjection of either p75NTR alone or p75NTR and Bcl-2 constructs
failed to increase neuronal death in the presence of NGF. E, death
induced by withdrawal of NGF is inhibited by expression of the micro-
injected Bcl-2 plasmid. l, uninjected and, f, Bcl-2-injected neurons in
NGF; E, uninjected and, , Bcl-2-injected neurons after factor with-
drawal. *, p , 0.05; ** p , 0.01; *** p , 0.001; error bars indicate S.E.,
n 5 3.
FIG. 4. Effects of survival-inactive Bcl-2 proteins on p75NTR-
mediated killing. Mutant Bcl-2 plasmids were injected into neurons
in the presence of LIF, either alone or together with p75NTR, and the
neurons were assessed for mortality 16 h after injection. A, Bcl-2 G145E
expression has no effect on cell survival and does not enhance or protect
against the effects of p75NTR killing. B, Bcl-2 W188A totally inhibited
p75NTR killing reminiscent of Bcl-xL (compare with Fig. 3A). ** p ,
0.01; ***p , 0.001; error bars indicate S.E., n 5 3.
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death pathway such that an apoptotic stimulus via p75NTR
results in rapid cell death. We examined whether Bcl-2 may not
only enhance p75NTR killing but may be essential for p75NTR
killing to proceed by testing whether lowering endogenous
Bcl-2 would inhibit p75NTR-mediated killing. We used a Bcl-2
antisense plasmid, which has previously been shown to effec-
tively lower Bcl-2 expression after microinjection into neurons
(26, 27). When the Bcl-2 antisense plasmid was injected at the
same time as the p75NTR plasmid, no diminution of the death
signal was seen. If, however, the neurons were microinjected in
the presence of NGF, to give time for the antisense to deplete
endogenous Bcl-2, and then switched into LIF the next day to
permit p75NTR killing, there was a significant decrease in the
ability of p75NTR to kill neurons with lowered Bcl-2 (Fig. 5A);
in fact, the level of killing was not significantly different from
that of neurons expressing p75NTRnc (Fig. 5A). The specificity
of the Bcl-2 antisense was demonstrated by its inability to
affect neuronal survival when expressed alone or in conjunc-
tion with p75NTRnc (data not shown). In addition, a control
vector expressing green fluorescent protein had no affect on
p75NTR killing (data not shown).
The requirement for endogenous Bcl-2 for p75NTR killing
was also demonstrated in neurons from newborn mice lacking
Bcl-2, which showed a significant reduction in cell death in-
duced by p75NTR compared with wild-type litter mates (Fig.
5B), supportive of the Bcl-2 antisense experiments.
To investigate whether the p75NTR-Bcl-2 death-signaling
cascade was dependent on caspase activation, a modified
CrmA, designed to inhibit downstream group II caspases, such
as caspase 3 (28, 29), was overexpressed together with
p75NTR. The modified CrmA was able to block the killing
induced either by p75NTR alone or by co-expression of p75NTR
and Bcl-2 in wild-type neurons (Fig. 5C), suggesting that
p75NTR-Bcl-2-induced apoptosis utilizes a caspase-dependent
pathway.
DISCUSSION
Bcl-2 has been shown to be cleaved by caspases, with the
cleavage product being capable of promoting apoptosis in vitro
(30). Cleavage of Bcl-2 may occur in our system but the mu-
tated Bcl-2 proteins would be similarly cleaved, arguing that
cleavage of Bcl-2 is unlikely to be the dominant mechanism by
which Bcl-2 promotes killing in our system. In addition, if
caspase cleavage was the dominant mechanism, Bcl-xL might
also be expected to promote death in our system as Bcl-xL has
been shown to be cleaved in a similar way (31).
Bcl-2 and Bcl-xL are likely to have a very similar tertiary
structure based on sequence similarity. The NMR structure of
Bcl-xL has been determined, showing a hydrophobic cleft
formed by seven a helixes where other Bcl-2 family proteins
interact (32). Bcl-xL, and Bcl-2, may function differently by
specific interaction with proteins that mediate p75NTR-in-
duced death. For example, pro-apoptotic Bcl-2 family members,
Bak and Bad, interact strongly with Bcl-xL but weakly with
Bcl-2 (33, 34). Also, Bcl-xL, but not Bcl-2 as yet, has been shown
to interact with Apaf-1, the mammalian CED-4 homologue, to
regulate apoptosis via caspase-9 activation (35). Mutation of
Bcl-2 at Gly-145 or Trp-188 may affect its interaction with pro-
and anti-apoptotic proteins by conformational changes disrupt-
ing access to the cleft. This suggests that the conformation of
the Bcl-2 protein is integral to the paradoxical functions ob-
served herein and that Bcl-2 participates in the p75NTR-kill-
ing pathway and stress-induced survival by different molecular
mechanisms.
The different neuronal phenotype observed in Bcl-2- and
Bcl-xL-deficient animals is consistent with our results that
Bcl-2 and Bcl-xL can have quite different functions in regulat-
ing neuronal death. Mice deficient for Bcl-xL have a major loss
of neurons shortly after their differentiation (36), whereas Bcl-
2-deficient mice show only minor loss of neurons during em-
bryogenesis and early neonatal life (37).
The latter phenotype would support the idea that during
development Bcl-2 plays two contrasting roles: under condi-
tions where there are appropriate neuritic connections leading
to trk signaling, Bcl-2 may act to enhance neuronal survival, as
has been shown for trigeminal sensory neurons in vitro (26, 27);
alternatively, as observed, Bcl-2 may also be capable of promot-
ing neuronal death at other stages, for example when neurons
may become more dependent on neural cytokine (e.g. LIF,
CNTF, OsM) support in early postnatal development (38, 39).
The LIF family signal through Janus tyrosine kinase/signal
transducer and activator of transcription (JAK/STAT) path-
ways, which can be inhibited by the neurotrophin-activated
mitogen-activated protein (MAP) kinase pathway (40). Thus, it
is possible that the in vivo switch of neuron dependence be-
tween neurotrophins and neural cytokines may prime the neu-
rons to cell death. Activation of p75NTR then may occur
FIG. 5. Bcl-2 and caspases are required for p75NTR-induced
cell death. A, neurons expressing both p75NTR and antisense Bcl-2
show a significant increase in survival compared with p75NTR alone
and have no increased mortality compared with neurons expressing
control plasmid p75NTRnc. B, neurons from Bcl-2-deficient mice and
their in wild-type littermates were injected with either p75NTR or
p75NTRnc, and the degree of killing because of p75NTR was calculated.
Bcl-2-deficient neurons are significantly less susceptible to killing by
p75NTR overexpression. C, neurons were injected with either modified
CrmA, or p75NTR and Bcl-2, or all three together. Expression of mod-
ified CrmA alone had no effect on neuronal survival, but significantly
inhibited death induced by p75NTR and Bcl-2 expression. * p , 0.05; **
p , 0.01; error bars indicate S.E., n 5 3.
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through NGF or BDNF signaling as has been recently shown
(10, 41).
The apparent paradoxical actions of Bcl-2 may be a program
by which rapid selection of cell survival or death occurs during
neuronal development and after nerve injury. There are high
levels of Bcl-2 in neurons of both the central and peripheral
nervous systems during periods of developmental cell death
(42), and activation of p75NTR, also expressed widely in the
nervous system during development, in the presence of high
Bcl-2, would lead to rapid apoptosis.
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